Anthem Biosciences Limited (ANTHEM) Fair Value & Analysis
Healthcare · IN · Market cap ₹436B
Fair value as of: Jul 18, 2026
From 24 valuation models · updated 23 days ago
Fair value updated Jul 18, 2026, revised from ₹211.75 to ₹196.91 (−7.0%) since Jul 14, 2026. Share price +12.4% over the past month.
A solid business, but screening 77% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (₹346.59). The favourable scenario is already priced in.
- Solid but not exceptional quality (66/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (₹148.66 to ₹346.59) leaves room in how you read the outcome.
Price vs Fair Value (13 months)
White line = price, green steps = our fair value per fiscal year. As of Jul 18, 2026.
How to read this chart
13‑month range ₹586.32 – ₹862.25 · fair‑value band ₹148.66 – ₹346.59 · the ₹841.00 price screens above the ₹196.91 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Jul 18, 2026.
Analysis
Anthem Biosciences Limited (ANTHEM) currently trades at ₹841.00, while our model-based Fair Value estimate is ₹196.91, implying the stock looks roughly 76.6% overvalued today. The Quality Score stands at 66/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Anthem Biosciences Limited generated revenue of ₹21.2B at a net margin of 27.9%. Revenue grew 26.4% year over year. It earns a return on equity of 21.7%. The balance sheet holds a net cash position of ₹2.2B. Fundamentals as of Jul 18, 2026
Our scenario range runs from ₹148.66 (bear case) to ₹346.59 (bull case); at ₹841.00, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 4% below its 52-week high and 45% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -77%, ANTHEM screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (₹332.82) versus Asset-Based (₹36.29). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 18, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 67 · Market factors (momentum, volatility) 64
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients.
Full company description
Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of molecules used for clinical Phase I, II, and III trials up to commercial manufacturing of RNA-based therapies, antibody-drug conjugates, peptides and oligonucleotides, lipids, biologics and biotherapeutics, fermentation, biosynthesis and biotransformation, and flow chemistry. It also manufactures and sells complex specialized fermentation-based active pharmaceutical ingredients (APIs), including serratiopeptidase protease and vitamin K2; microbial and mammalian biosimilars; probiotics, such as bacillus species, lactobacillus species, bifidobacterium species, streptococcus species and saccharomyces boulardii; enzymes; peptides, including semaglutide, plecanatide, linaclotide, liraglutide, and cilengitide; nutritional actives, vitamin analogues, and APIs. The company was incorporated in 2006 and is based in Bengaluru, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Anthem Biosciences Limited reported revenue of ₹21.2B in FY2026 versus ₹12.3B in FY2022, a compound +14.6%/yr. Reported net income was ₹5.9B in FY2026, compounding +9.9%/yr from FY2022.
ANTHEM screens 77% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 603 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 45/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare Anthem Biosciences Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Anthem Biosciences Limited (ANTHEM) overvalued or undervalued?
What is the fair value of ANTHEM?
What is the quality score of ANTHEM?
What is the revenue of Anthem Biosciences Limited (ANTHEM)?
What is the net profit margin of ANTHEM?
Does Anthem Biosciences Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Anthem Biosciences Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.